-
公开(公告)号：US12042524B2
公开(公告)日：2024-07-23
申请号：US17231981
申请日：2021-04-15
CPC分类号： A61K38/02 , A61K38/16 , C07K14/001 , C07K14/47 , C07K16/2863 , A61K38/00 , C07K5/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US11981738B2
公开(公告)日：2024-05-14
申请号：US16757959
申请日：2018-10-25
申请人： Acceleron Pharma Inc. , Adimab, LLC
IPC分类号： A61K39/395 , A61P3/06 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2863 , A61P3/06 , A61K2039/505 , C07K2317/34 , C07K2317/92
摘要： The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.
-
公开(公告)号：US20220242956A1
公开(公告)日：2022-08-04
申请号：US17615474
申请日：2020-05-29
摘要： This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20170281711A1
公开(公告)日：2017-10-05
申请号：US15456392
申请日：2017-03-10
申请人： Acceleron Pharma Inc. , Adimab, LLC
摘要： This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20220119491A1
公开(公告)日：2022-04-21
申请号：US17245123
申请日：2021-04-30
发明人： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
-
公开(公告)号：US11279746B2
公开(公告)日：2022-03-22
申请号：US16803230
申请日：2020-02-27
IPC分类号： C07K14/705 , C07K14/71
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
-
公开(公告)号：US10738098B2
公开(公告)日：2020-08-11
申请号：US16158661
申请日：2018-10-12
IPC分类号： C07K14/705 , C07K14/71
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
-
公开(公告)号：US20190218272A1
公开(公告)日：2019-07-18
申请号：US16354709
申请日：2019-03-15
IPC分类号： C07K14/705 , C07K14/71
CPC分类号： C07K14/705 , C07K14/71 , C07K2319/30
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
-
公开(公告)号：US10227392B2
公开(公告)日：2019-03-12
申请号：US15092577
申请日：2016-04-06
发明人： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
-
10.发明申请公开(公告)号：US20160289298A1
公开(公告)日：2016-10-06
申请号：US15092600
申请日：2016-04-06
发明人： Ravindra Kumar , Asya Grinberg , Dianne Sako
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/30
摘要： In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.
摘要翻译： 在某些方面，本公开提供了包含TGF-β家族的I型丝氨酸/苏氨酸激酶受体的细胞外结构域或TGF-β家族的II型丝氨酸/苏氨酸激酶受体的细胞外结构域的可溶性单臂异聚多肽复合物， beta家族 在一些实施方案中，本公开提供包含选自以下的II型受体的细胞外结构域的可溶性单臂多肽复合物：ActRIIA，ActRIIB，TGFBRII，BMPRII和MISRII。 在一些实施方案中，本公开提供了包含选自以下的I型受体的细胞外结构域的可溶性单臂多肽复合物：ALK1，ALK2，ALK3，ALK4，ALK5，ALK6和ALK7。 任选地，可溶性复合物是异二聚体。 在某些方面，这些可溶性多肽复合物可用于治疗或预防各种TGF-β相关病症，包括但不限于与例如癌症，肌肉，骨骼，脂肪，红细胞，代谢， 纤维化和受TGF-β超家族中一个或多个配体影响的其他组织。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.037 秒)
